Our present findings support the hypothesis that metformin improves the survival of breast cancer patients with concurrent diabetes, particularly in cases with hormone-responsive and HER2-positive tumors, receiving adjuvant systemic therapy. Here, ERBB2 is linked to breast carcinoma.